As type 2 diabetes becomes increasingly common in children, the need for reliable treatment options has never been greater. A new Eli Lilly study shows that Mounjaro’s the potential to improve blood sugar and overall metabolic health in young patients. In this article, you’ll find a clear breakdown of the study, the key findings, and the implications for paediatric diabetes care.
Type 2 diabetes in children has been rising at an alarming rate, and current treatment options often fall short of providing strong, sustained blood sugar control. Against this backdrop, Eli Lilly has released new late-stage clinical data suggesting that Mounjaro (tirzepatide) could become a promising addition to paediatric diabetes care.
The Phase 3 SURPASS-PEDS trial, involving children aged 10 to 17 years, found that Mounjaro delivered major improvements in blood sugar, weight, and overall metabolic health when added to standard treatments like metformin or insulin. While the medication is not yet approved for children, the findings have sparked significant interest among clinicians and health agencies evaluating new options for young patients.
Rising obesity rates, changes in diet, and reduced physical activity have all contributed to this surge, leaving health systems concerned about long-term complications beginning earlier in life.
For children, available therapies are limited mostly to metformin, insulin, and a small number of GLP-1 medications. Unlike adults, paediatric patients do not have access to a wide range of modern diabetes treatments, leaving many families struggling to maintain healthy blood sugar levels.
When type 2 diabetes develops in childhood, it tends to worsen faster and lead to health problems much earlier than in adults. Poorly controlled blood sugar in childhood raises lifetime risks of heart disease, kidney problems, and vision loss.
Because children are still developing, clinicians need treatments that improve metabolic control without compromising safety. This is why trials like SURPASS-PEDS are so important; they help determine whether new medicines can offer stronger control while remaining safe for young bodies.
In the study, children receiving Mounjaro saw far greater reductions in HbA1c compared with those on placebo. Average HbA1C dropped by over two percentage points, a clinically meaningful improvement, bringing many participants close to normal blood sugar ranges.
A striking proportion of children on Mounjaro reached recognised blood sugar targets:
These outcomes far surpassed results in the placebo group, demonstrating Mounjaro’s potential to stabilise blood sugar more reliably than current options alone.
Weight management plays a central role in treating paediatric type 2 diabetes. In the trial, children taking Mounjaro experienced notable reductions in BMI:
These changes contrast sharply with the placebo group, which saw almost no meaningful weight reduction. Because excess weight is strongly linked to insulin resistance in young people, this improvement is a significant clinical benefit.
Beyond blood sugar and weight, the data suggested broader metabolic improvements. Children on Mounjaro showed better glycaemic stability, fewer spikes and dips, which may help reduce long-term risks associated with early-onset diabetes.
Researchers note that better control in adolescence could translate to fewer complications later in life, though long-term studies will be needed to confirm this.
The safety results in children were generally similar to those observed in adults. The most common side effects were gastrointestinal:
Only a small number of participants discontinued treatment due to side effects. Importantly, no new safety concerns specific to children were identified. However, clinicians emphasise that paediatric patients require careful monitoring when prescribed any diabetes medication, especially one that affects appetite, weight, and blood sugar levels.
Mounjaro is different from other diabetes medicines because it targets two receptors instead of one:
This dual action helps the body:
Compared with older treatments like metformin or insulin, Mounjaro offers a broader metabolic effect. This is why researchers were interested in evaluating whether similar benefits could be safely extended to younger patients.
Following the trial, Eli Lilly has submitted data to regulators, including the MHRA and EMA. These agencies will now review:
Approval processes for paediatric medicines are stricter, as regulators must ensure the treatment is appropriate for bodies that are still growing. While the trial results are promising, approval is not guaranteed and may take time.
Experts believe the SURPASS-PEDS results represent an important milestone in paediatric diabetes research. If approved, Mounjaro could become one of the most effective tools for helping young people manage type 2 diabetes more safely and successfully.
The findings also highlight the need for:
As childhood diabetes becomes more common globally, expanding treatment options will be essential to protect long-term health.
The Care Pharmacy provides trusted, UK-regulated support for families managing diabetes. While Mounjaro is not currently approved for children, our clinicians help adults understand available treatment options, review safety considerations, and provide guidance that aligns with NHS best practice.
We also ensure:
For families monitoring new research and emerging treatments, our team is here to offer clarity, reassurance, and ongoing support.
Medically reviewed by
Superintendent Pharmacist
If you have spent any time reading online discussions about Mounjaro, you may have come across a phrase that sounds almost too good to be true: the Mounjaro golden dose. Some people describe it as an “extra” amount of medication hidden inside the pen, and others claim it is a bonus dose that can be […]
Mounjaro has recently been approved by MHRA for chronic weight management and has got a lot of media attention since its launch. As obesity and diabetes often go hand-in-hand, finding effective treatments that address both issues is crucial. In this article, we will explore the potential weight loss outcomes for patients using Mounjaro, how much […]
